UCLA stem cells scientists make electrically active motor neurons from iPS cells
Discovery demonstrates the feasibility of using iPS-derived motor neurons to model and treat diseases
Stem cells scientists at UCLA showed for the first time that human induced pluripotent stem (iPS) cells can be differentiated into electrically active motor neurons, a discovery that may aid in studying and treating neurological disorders.

Additionally, the motor neurons derived from the iPS cells appeared to be similar in function and efficiency to those derived from human embryonic stem cells, although further testing needs to be done to confirm that. If the similarities are confirmed, the discovery may open the door for new treatments for neurological disorders using patient-specific cells.

The study appears today in the early online edition of the journal Stem Cells. It can be accessed here: http://www.stemcells.com/view/0/index.html.

"It is clear from the literature that you can make at least immature versions of many different kinds of cells from human iPS cells," said William Lowry, a Broad Stem Cell Research Center scientist, an assistant professor of molecular, cell and developmental biology and senior author of the study. "But there is not a lot of data published describing the generation of fully functional cells from human iPS cells."

Lowry and his team used skin fibroblasts and reprogrammed them back into an embryonic state, with the ability to differentiate into any cell type in the human body. They then took those cells and differentiated them into motor neurons.

Neurons are the responsive cells in the nervous system that process and transmit information by electrochemical signaling. Motor neurons receive signals from the brain and spinal cord and regulate muscle contraction.

The study demonstrates the feasibility of using iPS-derived motor neurons and their progenitors to replace damaged or dead motor neurons in patients with certain disorders. It also opens the possibility of studying motor neuron-related diseases in the laboratory to uncover their causes. Motor neurons are lost in many conditions, including spinal cord injury, Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy.

"A primary objective of human embryonic stem cell and human iPS cell technology is to be able to generate relevant cell types to enable the repair of tissue damage and in vitro modeling of human disease processes," the study states. "Here, we demonstrate the successful generation of electrically active motor neurons from multiple human iPS cell lines and provide evidence that these neurons are molecularly and physiologically indistinguishable from motor neurons derived from human embryonic stem cells."

Much may be learned from studying the iPS-derived motor neurons and comparing them to motor neurons derived from patients with neurological disorders to see how they differ. The next step for Lowry and his team is to combine the motor neurons with muscle cells to see if they can stimulate a response. If they do, researchers should be able to see the muscle cells contract.


###

The study was funded in part by the California Institute for Regenerative Medicine, the state agency that administers Proposition 71 stem cell research funding, and was the result of a highly collaborative effort between Lowry's lab and other UCLA Broad Stem Cell Research Center faculty including Bennett Novitch, Harley Kornblum and Martina Wiedau-Pazos.

The stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 150 members, the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research is committed to a multi-disciplinary, integrated collaboration of scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The institute supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed towards future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine, UCLA's Jonsson Cancer Center, the Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science. To learn more about the center, visit our web site at http://www.stemcell.ucla.edu.




Public release date: 24-Feb-2009
[ Print Article | E-mail Article | Close Window ]

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-435-9457
University of California - Los Angeles